The Onco'Zine Brief

In this episode of The Onco’Zine Brief Peter Hofland talks with Stephen Spellman. Stephen Spellman is Vice President and Senior Scientific Director at Be The Match and the Center for International Blood & Marrow Transplant Research ( CIBMTR ). Hofland and Spellman talk about the outcomes of a study published in Blood Advances , the journal of the American Society of Hematology . [1] The articl...

In a new episode of The Onco’Zine Brief , Peter Hofland talks with Ely Benaim, MD, the Chief Medical Officer and Executive Vice President Development at SonALAsense and Mark De Souza, Ph. D, President and Chief Executive Officer of SonALAsense . SonALAsense was founded to create hope in the face of despair with Sonodynamic Therapy (SDT), a non-invasive therapy option using SONALA-001 in combinatio...

In a new episode of The Onco’Zine Brief , Peter Hofland talks with Jeffery Auletta, MD is Senior Vice President, Patient Outcomes and Experience, National Marrow Donor Program® (NMDP)/Be The Match®. Be The Match® is a global leader in bone marrow transplantation. The organization conducts research to improve transplant outcomes provide support and resources for patients, and partner with a global...

 In a new episode of The Onco'Zine Brief, Peter Hofland talks with David M. Cognetti, MD, a Professor and Chair in the Department Head and Neck Surgery at Thomas Jefferson University Hospital in Philadelphia. Hofland and Cognetti talk about head and neck cancer and a novel treatment approach called Photoimmunotherapy. Head and Neck Cancer According to the American Cancer Society , Head and neck ca...

 In this episode of The Onco'Zine Brief, Peter Hofland talks with two experts about their research and the impact the outcomes from these studies may have on the treatment of patients diagnosed with cancer. First, Hofland talks with Christopher Heery, MD. Dr Heery is a board-certified medical oncologist with primary expertise in the translational and clinical development of immunotherapies, includ...

Antibody-drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. However, unlike chemotherapy, ADCs are intended to directly target and kill tumor cells while, at the same time sparing normal, healthy cells. Antibody-drug conjugates consist of three parts: an antibody specific to the target associated antigen, a payload (sometimes calles a...

In December 2022 the annual meeting of the American Society of Hematology took place in the vibrant city of New Orleans and brought together tens of thousands of participants from across the world to present and discuss the results of studies that ranged from initial hypothesis to practice-changing results. In this episode of The Onco’Zine Brie f Peter Hofland talks to two people about their resea...

In the 100th episode of the Onco’Zine Brief, Peter Hofland, Ph. D. talks with Stephen Spellman, Vice President of Research and Senior Scientific Director of the Center for International Blood and Marrow Transplant Research at the National Marrow Donor Program/Be the Match. In the program today Hofland and Spellman talk about bone-marrow transplants. The likelihood of finding a fully matched unrela...

In this edition of The Onco'Zine Brief, Peter Hofland, Ph. D, talks with Susanna F. Greer, Ph. D. the Chief Scientific Officer of the V Foundation. In her role, Dr. Greer is a visionary ambassador of the V Foundation, who works with the foundation’s Scientific Advisory Committee to steer funding to the most promising research opportunities. An accomplished strategist, she develops and articulates...

Despite availability of endocrine therapies for advanced or metastatic breast cancer, there remains a critical unmet need for more effective and convenient treatment options that improve both the patient experience and health outcomes. In today’s episode of The Onco’Zine Brief, Peter Hofland, Ph. D. talks with Sean P. Bohen, MD, Ph. D., the president and Chief Executive Officer of Olema Therapeuti...

The annual congress of the European Society for Medical oncology or ESMO, is one of the most influential oncology meetings for clinicians, researchers, patient advocates, and healthcare industry representatives from all over the world. This year the annual Congress was held September 9 - 13, 2022 in the Paris Expo Porte de Versailles in Paris, France. In this episode of the Onco’Zine Brief, Peter...

Glioblastoma is an aggressive type of cancer that can occur in the brain or spinal cord. And while the disease can occur at any age, it tends to occur more often in older people. According to the American Cancer Society, United States, doctors diagnose between 12,000 and 14,000 patients with glioblastoma in the U.S. each year. There is currently no cure for glioblastoma. The median length of survi...

Your annual doctors- (or wellness-) visit may not be enough to prevent diseases like cancer. Daily health and lifestyle choices are the key to cancer prevention - but what are these choices? What is important? In "It’s Time you Knew’ - The Power of Your Choices to Prevent Women's Cancer", board certified gynecological oncologist Dr Valene Wright offers simple and straightforward tools to help wome...

After checking your cholesterol, hemoglobin A1C, and glucose level during your annual wellness check, your primary care phycisian says: 'It looks like we haven't done your genome. Why don't we do that?' How would you respond? If you have a genetic mutation that increases your risk for a treatable medical condition, would you want to know? For many people the answer is yes. But typically, such info...

Research out earlier this year confirms what many doctors had feared: Cancer screenings dropped significantly during the Covid-19 pandemic. The study, published in the February 2022 edition of Journal of the National Comprehensive Cancer Network, examined data from the Ontario Cancer Registry in Canada. The results showed that in March 2020 the week-to-week rate of cancer diagnosis dropped by 34.3...

In the past 30 years, the survival rate for breast cancer has improved by about 40%, one of the highest survival rates of any cancer. The increase in survival is, in part, due to advances in screening technology as well as improvement in cancer treatment and a better understanding of the biology of cancer. All of which have had an impact on survival. In this episode of The Onco’Zine Brief Peter Ho...

Cancer remains the second leading cause of death in the world, and numbers are on the rise. To respond to the growing need for therapeutic solutions, much research is needed. In this episode of The Onco’Zine Brief Peter Hofland, Ph. D. talks with Susan Pandya, MD. Pandya is Vice President Clinical Development and Global Head of Cancer Metabolism at Servier Pharmaceuticals. She is also a board-cert...

In this episode of The Onco’Zine Brief Peter Hofland Ph. D. talks with Ellen J. Kim, MD. Kim is the Medical Director of the Dermatology Clinic at the Perelman Center for Advanced Medicine and Professor of Dermatology at the Hospital of the University of Pennsylvania. She is also the Lead Principal Investigator for the Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study in cutaneo...

In this episode of The Onco’Zine Brief Peter Hofland, Ph. D. talks with Eyal Talor, Ph. D., a clinical immunologist with over 25 years of hands-on management experience in clinical research and drug development. Talor joined CEL-SCI in October 1993 and was promoted to Chief Scientific Officer in October 2009. CEL-SCI is developing a new immunotherapeutic drug for the treatment of cancer, autoimmun...

In this episode of The Onco’Zine Brief Peter Hofland, Ph. D. talks with Diane Simeone, MD, the Committee Chair and Principal Investigator and Executive Committee Chair of the PRECEDE Consortium. Simeone is also the Laura and Isaac Perlmutter Professor of Surgery, Department of Surgery at NYU Grossman School of Medicine, Professor, Department of Pathology at NYU Grossman School of Medicine, Directo...

In this episode of The Onco’Zine Brief Peter Hofland, Ph. D. talks with Nader Sanai, MD. Dr. Sanai is the director of the Ivy Brain Tumor Center and the director of neurosurgical oncology at the Barrow Neurological Institute in Phoenix, Arizona. In this episode of the program Hofland asked Sanai about Phase 0 studies – also known as micro-dosing studies – and why they are so important in the devel...

In this episode of The Onco’Zine Brief, developed in collaboration with ADC Review | Journal of Antibody-drug Conjugates (at www. ADCReview.com ), Peter Hofland, Ph. D. talks with William (Bill) Newell, JD, Chief Executive Officer and a member of the Board of Directors of Sutro Biopharma ( www.sutrobio.com ) Sutro is a clinical-stage drug discovery, development, and manufacturing company using pre...

In this edition of The Onco’Zine Brief Peter Hofland, Ph. D., talks with Mondher Mahjoubi, MD, Chief Executive Officer and Chairman of the Executive Board of Innate Pharma, a clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Innate Pharma’s broad pipeline...

In this edition of The Onco’Zine Brief Peter Hofland, Ph. D talks with Tony Polverino, PhD. In September 2918 Polverino joined Zymeworks, a clinical-stage, biopharmaceutical company developing next-generation multifunctional biotherapeutics. He currently serves as the company's Executive Vice President of Early Development and Chief Scientific Officer. Prior to joining Zymeworks, from 2015 until 2...

In this edition of The Onco’Zine Brief Peter Hofland, Ph. D. talks with Yoav Kimchy, Ph. D. Kimchy has more than 20 years of experience in the development and management of innovative medical device companies. He founded Check-Cap in 2005 and served as the company's Chief Technology Officer. Check-Cap is a clinical-stage medical diagnostics company aiming to redefine colorectal cancer screening/ t...